Main Navigation

High profile treatments cut from cancer drugs fund

By 2015-09-04T17:02:00

Pills

High profile cancer treatments including Roche’s Kadcyla and Avastin are to be removed from the cancer drugs fund.

You need to be signed in to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of HSJ.co.uk and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Subscribe

to HSJ

Sign into your account here